<https://rdf.molmedb.upol.cz/reference/ref4044> <http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>;
	<http://purl.org/ontology/bibo/pmid> "31264862"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.9b00662"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM493354>,
		<https://rdf.molmedb.upol.cz/interaction/membrane21>;
	<http://purl.org/dc/terms/bibliographicCitation> "Kumar S, Waldo JP, Jaipuri FA, Marcinowicz A, Van Allen C, Adams J, Kesharwani T, Zhang X, Metz R, Oh AJ, Harris SF, Mautino MR.: Discovery of Clinical Candidate (1<i>R</i>,4<i>r</i>)-4-((<i>R</i>)-2-((<i>S</i>)-6-Fluoro-5<i>H</i>-imidazo[5,1-<i>a</i>]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1. J Med Chem, Volume 62 (14), 2019"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1030324> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4044> .
<https://rdf.molmedb.upol.cz/interaction/int1030325> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4044> .
